Investigational Drug Information for AZD-2624
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug AZD-2624?
AZD-2624 is an investigational drug.
There have been 33 clinical trials for AZD-2624.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2021.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and National Cancer Institute (NCI).
There are four US patents protecting this investigational drug and sixty-six international patents.
Summary for AZD-2624
| US Patents | 4 |
| International Patents | 66 |
| US Patent Applications | 36 |
| WIPO Patent Applications | 24 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2021-09-15) |
| Vendors | 17 |
Recent Clinical Trials for AZD-2624
| Title | Sponsor | Phase |
|---|---|---|
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | AstraZeneca | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Ministry of Health | Phase 3 |
| Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2 | Botswana Harvard AIDS Institute Partnership | Phase 3 |
Clinical Trial Summary for AZD-2624
Top disease conditions for AZD-2624
Top clinical trial sponsors for AZD-2624
US Patents for AZD-2624
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD-2624 | ⤷ Try a Trial | Method for treating or preventing hot flushes | Imperial Innovations Limited (Greater London, GB) | ⤷ Try a Trial |
| AZD-2624 | ⤷ Try a Trial | Indole derivative or pharmaceutically acceptable salt thereof | Kissei Pharmaceutical Co., Ltd. (Nagano, JP) | ⤷ Try a Trial |
| AZD-2624 | ⤷ Try a Trial | Indole derivative, and pharmacologically acceptable salt thereof | Kissei Pharmaceutical Co., Ltd. (Nagano, JP) Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP) | ⤷ Try a Trial |
| AZD-2624 | ⤷ Try a Trial | Indole derivative and pharmacologically acceptable salt thereof | Kissei Pharmaceutical Co., Ltd. (Nagano, JP) Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD-2624
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD-2624 | European Patent Office | EP3041509 | 2033-09-05 | ⤷ Try a Trial |
| AZD-2624 | United Kingdom | GB201315846 | 2033-09-05 | ⤷ Try a Trial |
| AZD-2624 | World Intellectual Property Organization (WIPO) | WO2015033163 | 2033-09-05 | ⤷ Try a Trial |
| AZD-2624 | Australia | AU2018388302 | 2037-12-19 | ⤷ Try a Trial |
| AZD-2624 | Australia | AU2018393073 | 2037-12-19 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
